LT3465214T - Anti-cd19 terapijos terapinės naudos pacientams prognozavimo metodai - Google Patents
Anti-cd19 terapijos terapinės naudos pacientams prognozavimo metodaiInfo
- Publication number
- LT3465214T LT3465214T LTEP17728484.1T LT17728484T LT3465214T LT 3465214 T LT3465214 T LT 3465214T LT 17728484 T LT17728484 T LT 17728484T LT 3465214 T LT3465214 T LT 3465214T
- Authority
- LT
- Lithuania
- Prior art keywords
- therapy
- patients
- methods
- therapeutic benefit
- predicting therapeutic
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16171885 | 2016-05-30 | ||
PCT/EP2017/063045 WO2017207574A1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3465214T true LT3465214T (lt) | 2021-10-11 |
Family
ID=56116221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP21170716.1T LT3916392T (lt) | 2016-05-30 | 2017-05-30 | Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai |
LTEP17728484.1T LT3465214T (lt) | 2016-05-30 | 2017-05-30 | Anti-cd19 terapijos terapinės naudos pacientams prognozavimo metodai |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP21170716.1T LT3916392T (lt) | 2016-05-30 | 2017-05-30 | Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai |
Country Status (27)
Country | Link |
---|---|
US (2) | US20190195879A1 (lt) |
EP (2) | EP3465214B1 (lt) |
JP (2) | JP7066639B2 (lt) |
KR (1) | KR102416144B1 (lt) |
CN (2) | CN115932265A (lt) |
AU (1) | AU2017272608B2 (lt) |
BR (1) | BR112018074603A2 (lt) |
CA (1) | CA3025823A1 (lt) |
CY (1) | CY1124768T1 (lt) |
DK (2) | DK3465214T3 (lt) |
EA (1) | EA201892542A1 (lt) |
ES (1) | ES2878156T3 (lt) |
FI (1) | FI3916392T3 (lt) |
HR (1) | HRP20210938T1 (lt) |
HU (1) | HUE054860T2 (lt) |
IL (1) | IL263103B2 (lt) |
LT (2) | LT3916392T (lt) |
MA (2) | MA57021B1 (lt) |
MD (1) | MD3465214T2 (lt) |
MX (2) | MX2018014702A (lt) |
PL (1) | PL3465214T3 (lt) |
PT (2) | PT3916392T (lt) |
RS (2) | RS65540B1 (lt) |
SG (2) | SG11201810159TA (lt) |
SI (1) | SI3465214T1 (lt) |
WO (1) | WO2017207574A1 (lt) |
ZA (1) | ZA201808647B (lt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220242952A1 (en) * | 2019-05-03 | 2022-08-04 | Morphosys Ag | Anti-cd19 therapy in patients having a limited number of nk cells |
TW202131950A (zh) * | 2019-10-31 | 2021-09-01 | 德商莫菲西斯公司 | 依序抗cd19療法 |
AU2020376305A1 (en) * | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
MX2023006538A (es) * | 2020-12-04 | 2023-08-08 | Morphosys Ag | Terapia combinada de anticuerpo anti cúmulo de diferenciación 19 (cd19). |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1320044A (zh) | 1998-08-11 | 2001-10-31 | Idec药物公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
CA2439410C (en) | 2001-02-27 | 2011-09-06 | William D. Figg | Analogs of thalidomide as potential angiogenesis inhibitors |
WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
DK1966245T3 (da) | 2005-12-30 | 2011-07-18 | Merck Patent Gmbh | Anti-CD19-Antistoffer med reduceret immunogenicitet |
AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
CA2662340C (en) | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
DE602007013068D1 (de) | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
LT2176298T (lt) | 2007-05-30 | 2018-04-10 | Xencor, Inc. | Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui |
DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
US20130330328A1 (en) | 2010-11-15 | 2013-12-12 | Medimmune, Llc | Combination Therapy For B Cell Lymphomas |
EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
PL2744515T3 (pl) | 2011-08-16 | 2022-05-30 | Morphosys Ag | Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym |
SG10201606788VA (en) * | 2011-08-16 | 2016-09-29 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a purine analog |
WO2013090478A1 (en) * | 2011-12-12 | 2013-06-20 | Pikamab, Inc | Predicting responsiveness to antibody maintenance therapy |
EP3110445A4 (en) * | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
WO2015195498A1 (en) * | 2014-06-16 | 2015-12-23 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
JP6805137B2 (ja) * | 2014-07-11 | 2020-12-23 | アンセルム(アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) | 血液学的癌を診断するための方法 |
-
2017
- 2017-05-30 CA CA3025823A patent/CA3025823A1/en active Pending
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 MX MX2018014702A patent/MX2018014702A/es unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active IP Right Grant
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt unknown
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-06-11 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284173A (en) | Methods for training patients for t-cell therapy | |
IL265759A (en) | Therapeutic and diagnostic methods for cancer | |
HK1250376A1 (zh) | 用於癌症的治療和診斷方法 | |
HK1248773A1 (zh) | 用於癌症的治療和診斷方法 | |
IL261422A (en) | Therapeutic and diagnostic methods for cancer | |
PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
ZA201703904B (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
IL262208A (en) | Diagnostic and therapeutic methods for cancer | |
ZA201808647B (en) | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients | |
HK1258128A1 (zh) | 選擇病人接受組合療程 | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1259077A1 (zh) | 使用用於bcg療法的生物標記來治療及診斷疾病的方法 | |
HK1255691A1 (zh) | 對疾病進行組織學診斷和治療的方法 | |
GB201600637D0 (en) | Therapeutic treatment methods and apparatus for use therein | |
GB201501202D0 (en) | Novel methods for diagnosis and therapy | |
GB201418640D0 (en) | Agents and methods for treatment of cancer |